Barriers and Challenges:

Although the nose-to-brain pathway circumvents the BBB, it still faces several obstacles. Enzymes in the nasal mucosa may break down some medications, lowering their bioavailability. The formulation of the medication, lipophilicity, and molecular size all have an impact on the rate of drug absorption. Another challenge is overcoming mucociliary clearance, which quickly removes undesirable objects from the nasal cavity³⁴.

Overview of Liposomal Drug Delivery Systems:

Both hydrophilic and hydrophobic medications can be encapsulated in liposomal drug delivery systems, which are adaptable nanoscale carriers composed of phospholipid bilayers. Liposomes have attracted a lot of attention since their discovery in the 1960s because of their special capacity to prevent drug degradation, improve bioavailability, and permit controlled drug release³⁵. To enable customized medication delivery, these vesicles' size, charge, and lipid composition can be altered³⁶.

Liposomal formulations are a perfect platform for brain-targeting therapeutics because they are especially good at delivering medications through biological barriers including the nasal mucosa and the blood-brain barrier³⁷. Liposomes' ability to bond with cellular membranes and carry therapeutic substances straight into cells is enhanced by their phospholipid bilayer structure, which resembles the normal cell membrane³⁸. Furthermore, liposomes have longer circulation durations and can avoid immune system recognition, which improves the efficacy of medications that would otherwise be quickly digested or eliminated from the body³⁹.

Types of Liposomes:

Liposomes are categorized according to their size and bilayer count:

i. Small Unilamellar Vesicles (SUVs): They are less than 100 nm and consist of a single lipid bilayer. They are commonly used to deliver small molecules and hydrophilic drugs⁴⁰.

ii. Large Unilamellar Vesicles (LUVs): With a single lipid bilayer and a bigger size than SUVs, these vesicles can contain more medications or larger molecules⁴¹.

iii. Multilamellar Vesicles (MLVs): MLVs, which are made up of many lipid bilayers, are employed when a regulated or prolonged release of a medicine is needed⁴².

Mechanism of Drug Delivery:

The primary advantage of liposomes is their ability to improve the pharmacokinetics and pharmacodynamics of encapsulated drugs. Liposomes can passively target inflammatory tissues or cancers by utilizing the increased permeability and retention (EPR) effect, which concentrates drugs in regions with leaky vasculature⁴³. Liposomes administered intranasally aid to pass the blood-brain barrier and provide direct access to the central nervous system⁴⁴.

Applications in Neurodegenerative Disorders:

Promising outcomes in Parkinson's disease and other neurological disorders have been shown by liposomal technologies⁴⁵. Neuroprotective medications are stabilized and their distribution to the brain is improved by liposome encapsulation, which also lowers systemic exposure and side effects⁴⁶. For chronic illnesses like Parkinson's disease (PD), where regular treatment is necessary for successful symptom control, this tailored delivery is especially advantageous⁴⁷.

Advantages of Liposomal Drug Delivery Systems:

i. Protection from Degradation: Liposomes increase the durability of encapsulated medications by shielding them from enzymatic or environmental destruction⁴⁸.

ii. Increased Bioavailability: Liposomes improve the solubility and absorption of medications that aren't very soluble in water⁴⁹.

iii. Targeted Delivery: Drugs can be delivered by liposomes to specific locations, minimizing negative effects and boosting therapeutic efficacy⁵⁰.

iv. Reduced Toxicity: Encapsulation reduces the toxicity of potent drugs by controlling their release.

In Situ Gels for Intranasal Delivery:

Novel drug delivery technologies called in situ gels provide a special way to administer medications intranasally. When exposed to physiological circumstances like temperature or pH changes, these gels are made to change from a liquid state to a gel-like structure. These features allow for easy administration and ensure long-lasting medication release at the site of action⁵¹. Numerous advantages, including longer residence time, improved bioavailability, and fewer doses, are provided by intranasal delivery in conjunction with in situ gel technology⁵².

Mechanism of Action:

The mechanism underlying in situ gel formation often uses temperature-sensitive polymers, ion-sensitive polymers, or pH-sensitive systems. When a liquid formulation is applied nasally, it interacts with the nasal mucosa and transforms into a gel that adheres to the tissue and gradually releases the medication that is encapsulated⁵³. This extended release can significantly improve therapeutic outcomes, particularly for drugs that require stable plasma levels to function⁵⁴.

Advantages of In Situ Gels:

i. Sustained Drug Release: Drugs can be released gradually and under control using in situ gels, reducing the need for frequent administration⁵⁵.

ii. Increased Bioavailability: These gels improve drug absorption and bioavailability by sticking to the nasal mucosa, so avoiding first-pass metabolism⁵⁶.

iii. Patient Compliance: Reduced dosage frequency and convenience of administration can improve patient compliance, which is important for long-term illnesses like Parkinson's disease⁵⁷.

Challenges and Considerations:

The creation of in situ gels for intranasal delivery is fraught with difficulties, despite their many benefits. Important elements that can affect the effectiveness of these systems include formulation stability, the selection of appropriate polymers, and the compatibility of active medicinal components⁵⁸. Furthermore, a crucial factor in the formulation process is maximizing the gelation time to guarantee a speedy transition while avoiding early gel formation during storage⁵⁹.

Strategies to Overcome Formulation Challenges:

The stability of liposomes and improving their adherence to the nasal mucosa for extended drug retention are two crucial issues that must be addressed in order to construct an efficient intranasal liposomal in situ gel. These problems can be resolved and the formulation's overall effectiveness raised with the use of the following tactics.

i. Enhancing Liposome Stability:

Liposomal formulations can degrade over time due to factors like oxidation, hydrolysis, and temperature fluctuations. The following strategies are commonly employed to maintain liposome integrity and ensure sustained drug release:

a) Sterically Stabilized Liposomes (Stealth Liposomes): Polyethylene glycol (PEG) coating increases the stability and shelf life of liposomes by enclosing the lipid bilayer in a protective layer that inhibits enzyme degradation and liposome aggregation⁶⁰. Additionally, by lowering immune system clearance, PEGylation guarantees longer circulation times in the body.

b) Antioxidants and Preservatives: Liposomal formulations are prone to oxidation, especially when phospholipids containing unsaturated fatty acids are used. The addition of antioxidants like vitamin E or butylated hydroxytoluene (BHT) can reduce oxidative degradation, while preservatives like parabens or benzyl alcohol can prevent microbial contamination⁶¹.

c) Lipid Composition Optimization: Because of their higher transition temperature (Tm), saturated phospholipids, such as distearoylphosphatidylcholine (DSPC), offer more stability. Furthermore, cholesterol can be added to the lipid bilayer to make the membrane more stiff, which lowers permeability and prevents medication leakage⁶².

ii. Improving Nasal Mucosa Adhesion:

Extending the length of pharmaceutical retention and absorption requires improving the formulation's adhesion to the nasal mucosa. To improve treatment outcomes, mucociliary clearance must be overcome.

a) Mucoadhesive Polymers: To improve mucoadhesion, polymers such as chitosan, carbopol, and hydroxypropyl methylcellulose (HPMC) can be added to the in situ gel. Because it is positively charged, chitosan in particular has exceptional mucoadhesive qualities. It increases the duration of residence and facilitates drug absorption by electrostatically adhering to the negatively charged nasal mucosa⁶³.

b) Temperature-Sensitive Polymers: Pluronic F127 and polxamer 407 are commonly utilized thermosensitive polymers because they go through a sol-to-gel transition at physiological temperatures. These polymers guarantee that the formulation stays liquid at room temperature for convenient administration and gel, prolonging the retention duration, when it comes into contact with the nasal environment⁶⁴.

c) Enzyme Inhibitors: Enzyme inhibitors, such as bacitracin or soybean trypsin inhibitor, can shield the medication from enzymatic breakdown and reduce degradation by nasal enzymes, increasing its total bioavailability⁶⁵.

iii. Overcoming Mucociliary Clearance:

Since mucociliary clearance quickly eliminates foreign particles, it presents a serious problem for intranasal medication delivery methods. Among the methods to extend nasal retention are:

a) Prolonged Nasal Retention: The formulation sticks to the nasal mucosa and resists clearance thanks to bioadhesive ingredients like chitosan or thermosensitive gels, providing continuous medication release and lowering the frequency of doses⁶⁶.

b) Controlled Drug Release Systems: In situ gel technology and liposomal encapsulation work together to create a dual mechanism for sustained release. To ensure long-lasting therapeutic effects, the gel matrix regulates the diffusion rate while the liposomes release the encapsulated medication gradually⁶⁷.

Combining Liposomes with In Situ Gels:

The combination of liposomes and in situ gel formulations is one potential treatment option for Parkinson's disease (PD). This combination addresses significant delivery-related problems and enhances the therapeutic potential of drugs like levodopa by fusing the unique features of both systems. In an attempt to improve therapeutic efficacy and drug delivery to the brain, a variety of bioactive compounds have been investigated for intranasal administration in the treatment of Parkinson's disease.

Advantages of the Combination:

i. Enhanced Drug Stability and Bioavailability

Liposomes improve the stability and bioavailability of sensitive medications by creating a protective habitat⁶⁸. By encapsulating levodopa in liposomes, it can be shielded from nasal cavity degradation and more of the active ingredient will enter the bloodstream and reach the brain⁶⁹.

ii. Sustained Release and Patient Compliance

The in situ gel component allows the encapsulated drug to be continuously delivered for an extended period of time. By lowering the frequency of administration, this feature can greatly increase patient compliance, which is essential for the treatment of long-term illnesses like Parkinson's disease⁷⁰. For both motor and non-motor disorders, maintaining steady blood medication levels can provide more stable treatment and reduce symptom management variations⁷¹.

iii. Targeted Delivery to the Central Nervous System

The intranasal route effectively circumvents the blood-brain barrier, enabling the direct delivery of drugs to the central nervous system^72,73. When in situ gels and liposomes collaborate to enhance this targeted delivery, levodopa can more readily pass through the nasal mucosa and enter the brain, where it can begin to act therapeutically^74,75.

1. Formulation Considerations:

Careful selection and adjustment of liposomal components and gelation properties are necessary for an efficient intranasal liposomal in situ gel formulation for Parkinson's disease. To improve drug retention and bioavailability in the nasal cavity, these components cooperate to balance stability, permeability, and controlled release.

i. Phospholipid Composition in Liposome Preparation:

Phospholipid selection is essential since it has a big impact on liposome properties like size, stability, and drug retention. For instance, DSPC (1,2-Distearoyl-sn-glycero-3-phosphocholine) is a long-chain, saturated phospholipid that gives liposomes excellent membrane stability and structural integrity, making it a popular option for intranasal formulations that require extended drug retention⁷⁶. Because of its higher phase transition temperature, DSPC is more stable and may withstand degradation by nasal mucosal enzymes, allowing for longer-lasting medication administration⁷⁷.

In addition to DSPC, DMPG (1,2-Dimyristoyl-sn-glycero-3-phosphoglycerol) is a phospholipid that improves formulation performance by adding a negative surface charge to encourage mucoadhesion. By interacting with the positively charged mucosal components, this negative charge lengthens the liposomes' retention period in the nasal cavity and improves drug absorption⁷⁸. Formulations intended to deliver drugs to the central nervous system (CNS), including dopamine-loaded DSPC liposomes, have shown these qualities⁷⁹. When taken intranasally, they exhibit better stability and brain targeting⁸⁰. Because of its higher nasal brain targeting, DMPG-containing liposomes have also demonstrated increased efficacy in administering rasagiline for Parkinson's disease⁸¹.

ii. Role of Cholesterol in Liposome Stability:

Cholesterol contributes equally to liposomal stability by increasing membrane stiffness and decreasing permeability. It creates a more stable structure and reduces the membrane's fluidity as it integrates into the lipid bilayer. Cholesterol's ability to fortify the liposome membrane in intranasal formulations results in reduced drug leakage, extended drug release, and longer circulation duration. This stabilizing function is especially important in the nasal region, where enzymatic degradation may compromise liposome integrity and reduce bioavailability⁸².

A 2:1 phospholipid-to-cholesterol ratio is typically used to balance stability and medication release, though this ratio can be altered depending on the therapeutic requirements⁸³. A 2:1 ratio levodopa-loaded DSPC/cholesterol formulation, for instance, demonstrated enhanced brain targeting and extended nasal residence, both of which are beneficial for Parkinson's disease treatment⁸⁴. Additionally, it has been shown that cholesterol-rich liposomes efficiently inhibit the enzymes that degrade amantadine, guaranteeing a steady and extended nasal delivery of the medication to the brain⁸⁵.

iii. Sol-to-Gel Transition Properties in In Situ Gels:

The sol-to-gel transition property is essential for intranasal delivery systems because it allows formulations to remain liquid for easy administration while solidifying into a gel inside the nasal cavity, ensuring controlled drug release and prolonging residence time. Pluronic F127 (poloxamer 407) is one of the temperature-sensitive polymers that is essential to this transition. When this polymer comes into contact with the nasal mucosa, it forms a stable gel at physiological temperatures, which is approximately 37°C. At lower temperatures (below 15°C), it remains liquid⁸⁶. By keeping the formulation in the nasal cavity, this temperature-dependent gelation offers sustained release and lessens the need for frequent doses.

Because of Pluronic F127's distinct hydrophilic-lipophilic balance, micelle production results in the gelation. Because of this characteristic, the gel can remain in place and withstand the quick mucociliary drainage that occurs after nasal delivery⁸⁷. To improve the interface with the nasal mucosa and prolong drug absorption and retention, mucoadhesive polymers like chitosan or carbopol can be used. For example, chitosan loosens cellular tight junctions to promote medication penetration of the nasal epithelium in addition to adhering well to mucosal surfaces⁸⁸.

Their demonstrated enhanced nasal residency and brain absorption of Parkinson's medications, such as rasagiline, has reinforced the therapeutic utility of thermosensitive gels containing Pluronic F127 and chitosan in the treatment of chronic neurological disorders⁸⁹. Rich in dopamine Furthermore, in preclinical models, pluronic-based gels showed superior CNS targeting and long-lasting therapeutic benefits, indicating the potential of thermosensitive gels in the treatment of neurodegenerative diseases⁹⁰.

iv. Formulation Optimization for Targeted Drug Delivery:

Liposomes and in situ gels must be used in conjunction with careful consideration of particle size, release rate, and encapsulation efficiency to guarantee successful CNS targeting. Smaller particles, usually with a diameter of less than 200 nm, have an easier time getting past the nasal mucosa and reaching the olfactory bulb⁹¹. Mucoadhesion is enhanced and the formulation's stay in the nasal cavity is prolonged by a minor surface charge, which can be either positive or slightly negative⁹².

Delivering an effective dose requires high encapsulation efficiency, which lowers the frequency of dosing, which is a major benefit for long-term illnesses like Parkinson's disease⁹³. For instance, mucoadhesive dopamine-loaded liposomal gels intended for nasal administration demonstrated enhanced bioavailability and encapsulation effectiveness, both of which are critical for long-term therapeutic benefit⁹⁴. In the treatment of Parkinson's disease, ropinirole-loaded intranasal gels were created to target the brain, minimizing peripheral adverse effects and improving therapeutic response⁹⁵.

FUTURE PERSPECTIVES:

As the understanding of Parkinson's Disease (PD) and its underlying mechanisms continues to evolve, future research will likely focus on optimizing intranasal drug delivery systems, particularly liposomal in situ gels, for more effective management of the disease. The following aspects will be crucial in shaping future perspectives:

i. Enhanced Formulation Strategies:

Future formulations will likely emphasize the development of hybrid systems that combine liposomes with other advanced drug delivery technologies, such as nanoparticles or hydrogels. This approach can enhance drug encapsulation efficiency, stability, and controlled release profiles^96,97. Research on the optimal composition and ratio of lipids and polymers will be critical to ensure that formulations not only improve bioavailability but also provide targeted delivery to brain regions affected by PD⁹⁸.

ii. Personalized Medicine:

Future Parkinson's disease treatments will heavily rely on the concept of personalized medicine. Customizing drug formulations based on each patient's distinct traits, such as genetic predispositions and specific symptomatology, can significantly improve therapeutic outcomes⁹⁹. Integrating pharmacogenomics with liposomal drug delivery systems will allow for more precise dosing strategies and reduce adverse effects associated with conventional therapies.

iii. Regulatory and Clinical Trials:

Thorough regulatory frameworks will be necessary to get from laboratory research to clinical applications. Future research must examine the long-term effects, safety, and effectiveness of intranasal liposomal formulations across a range of demographics¹⁰⁰. Clinical trials should focus on comparative studies between traditional oral levodopa therapies and novel intranasal delivery systems to establish clinical benefits.

iv. Technological Innovations:

More complex medication delivery systems will be made possible by developments in materials science and nanotechnology¹⁰¹. To increase the effectiveness of intranasal medications, for example, stimuli-responsive materials that release medications in response to certain biochemical signals or environmental changes could be employed¹⁰². monitoring of drug levels in the CNS through smart devices could provide real-time feedback to adjust dosages accordingly¹⁰³.

v. Long-term Impacts on Patient Quality of Life:

The ultimate objective of these developments is to enhance the quality of life for PD patients. Future studies should concentrate on lowering the burden of illness through better drug adherence and efficient symptom management, giving priority to patient-reported outcomes¹⁰⁴. By treating both motor and non-motor symptoms with innovative drug delivery techniques, Parkinson's disease care may be improved overall¹⁰⁵.

CONCLUSION:

The development of intranasal liposomal in situ gels for Parkinson's Disease treatment presents a significant advancement by addressing limitations of conventional oral levodopa therapy, such as inconsistent bioavailability and motor complications. By bypassing the blood-brain barrier, intranasal delivery offers a more direct and efficient route for brain targeting. Liposomal formulations enhance drug stability and bioavailability, while in situ gels improve retention and provide sustained release, offering a solution to conventional drug delivery challenges. Moreover, the liposomal formulation provides controlled release and targeted delivery of the drug directly to the brain, bypassing gastrointestinal and hepatic first-pass metabolism. These characteristics make this system an ideal candidate for non-invasive, patient-friendly therapies, offering better patient compliance and comfort. Further research is needed to optimize these systems, assess safety, and validate their clinical effectiveness in improving patient outcomes and quality of life.

REFERENCES:

1. Formulation and Evaluation of Acyclovir Loaded Transferosomal Gel for Transdermal Drug Delivery. J. Drug Delivery Ther. 2024; 14(9): 122-30.

2. Shewale SS, Mulla JAS. Non-Ionic Surfactant Vesicle (Niosome): A Novel Drug Delivery System. Indian Journal of Novel Drug Delivery. 2022; 14(3): 129-137.

3. Rane KA, Mulla JAS. Hyaluronic Acid-Coated Niosomes: A Promising Drug Delivery System with Potential Applications. Indian Journal of Novel Drug Delivery. 2024; 16(1): 11-19.

4. Olanow CW, Stocchi F. Levodopa: A new look at an old friend. Mov Disord. 2018; Jul; 33(6): 859-866. doi: 10.1002/mds.27216. Epub 2017 Nov 27. PMID: 29178365.

5. Shingate DM, Mulla JAS. Exploring Liposomes: Comprehensive Classification, Preparation Techniques, and Composition Insights. Indian Journal of Novel Drug Delivery. 2024; 16(2): 80-90.

6. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021; Jun 12; 397(10291): 2284-2303. doi: 10.1016/S0140-6736(21)00218-X. Epub 2021 Apr 10. PMID: 33848468.

7. Chakorkar SS, Mulla JAS. A novel corticosteroid cubosomes–For ocular drug delivery. Indo Am J Pharm Res. 2020;10: 775-84.

8. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017; Mar 23; 3: 17013. doi: 10.1038/nrdp.2017.13. PMID: 28332488.

9. Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and Dysfunction of the Blood-Brain Barrier. Cell. 2015; Nov 19; 163(5): 1064-1078. doi: 10.1016/j.cell.2015.10.067. PMID: 26590417; PMCID: PMC4655822.

10. Pooja M. Nikam, S.B. Gondkar, R.B. Saudagar. Brain Targeting Drug Delivery System: A Review. Asian J. Res. Pharm. Sci. 2015; 5(4): Oct.-Dec. 247-252.

11. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009; Sep 8; 379(1): 146-57. doi: 10.1016/j.ijpharm.2009.06.019. Epub 2009; Jun 23. PMID: 19555750.

12. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002; Dec 1; 7(23): 1184-9. doi: 10.1016/s1359-6446(02)02529-1. PMID: 12547019.

13. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics. 2017; Mar 27; 9(2): 12. doi: 10.3390/pharmaceutics9020012. PMID: 28346375; PMCID: PMC5489929.

14. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013; Feb 22; 8(1): 102. doi: 10.1186/1556-276X-8-102. PMID: 23432972; PMCID: PMC3599573.

15. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012; May 15; 64(7): 614-28. doi: 10.1016/j.addr.2011.11.002. Epub 2011 Nov 15. PMID: 22119441.

16. Ravi PR, Aditya N, Patil S, Cherian L. Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv. 2015; 22(7): 903-10. doi: 10.3109/10717544.2013.860501. Epub 2013 Nov 29. PMID: 24286183.

17. Mabrouk M, Mulla JA, Kumar P, Chejara DR, Badhe RV, Choonara YE, du Toit LC, Pillay V. Intestinal targeting of ganciclovir release employing a novel HEC-PAA blended lyomatrix. AAPS PharmScitech. 2016; Oct; 17(5): 1120-30.

18. Sharma G, Sharma AR, Lee SS, Bhattacharya M, Nam JS, Chakraborty C. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. Int J Pharm. 2019; Mar 25; 559: 360-372. doi: 10.1016/j.ijpharm.2019.01.056. Epub 2019 Feb 2. PMID: 30721725.

19. Shirke SN, Mulla JAS. Intranasal nanoemulsion for brain targeting: A review. Indian Journal of Novel Drug Delivery. 2023; 15(1): 1-11.

20. Crowe TP, Hsu WH. Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System. Pharmaceutics. 2022; Mar 12; 14(3): 629. doi: 10.3390/pharmaceutics14030629. PMID: 35336004; PMCID: PMC8950509.

21. Bansal A, Deval A. Nanocarriers for brain targeting: Recent advances. Drug Delivery and Translational Research. 2021; 11(5): 1251–1269.

22. Landis MS, Ogden T. Nasal spray drug delivery for central nervous system therapies. Journal of Drug Delivery Science and Technology. 2019; 49: 11–19.

23. Kulkarni AD, Vanjari YH, Sancheti KH, Belgamwar VS, Surana SJ, Pardeshi CV. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review. J Drug Target. 2015; 23(9): 775-88. doi: 10.3109/1061186X.2015.1020809. Epub 2015 Mar 11. PMID: 25758751.

24. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013; Feb; 3(1): 42-62. doi: 10.1007/s13346-012-0108-9. Epub 2012 Oct 18. PMID: 23316447; PMCID: PMC3539067.

25. Mittal R, Debs LH, Patel AP, Nguyen D, Patel K, O'Connor G, Grati M, Mittal J, Yan D, Eshraghi AA, Deo SK, Daunert S, Liu XZ. Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis. J Cell Physiol. 2017; Sep; 232(9): 2359-2372. doi: 10.1002/jcp.25518. Epub 2017 Apr 10. PMID: 27512962; PMCID: PMC5772764.

26. Kalaiselvi S, Manimaran V, Damodharan N. Nanoparticle as a powerful tool to penetrate the Blood-brain barrier in the treatment of Neurodegenerative disease: Focus on recent advances. Research J. Pharm. and Tech. 2020; 13(5): 2135-2143.

27. Liji Jacob, Manju Salim S, Jilby Saju. Formulation and Evaluation of Transdermal Patches of Selegiline. Asian Journal of Pharmacy and Technology. 2022; 12(2): 96-0.

28. LeWitt, P. A., Hauser, R. A., Pahwa, R., Isaacson, S. H., Fernandez, H. H., Lew, M., Saint-Hilaire, M., Pourcher, E., Lopez-Manzanares, L., Waters, C., Rudzínska, M., Sedkov, A., Batycky, R., Oh, C., & SPAN-PD Study Investigators (2019). Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Neurology, 18(2), 145–154. https://doi.org/10.1016/S1474-4422(18)30405-8

29. Isaacson SH, et al. Parkinsonism and Related Disorders. Parkinsonism and Related Disorders. 2020; 74: 1–9. doi: 10.1016/j.parkreldis.2020.04.022

30. Hossen S, Hossain MK, Basher MK, Mia MNH, Rahman MT, Uddin MJ. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J Adv Res. 2018; Jun 25; 15: 1-18. doi: 10.1016/j.jare.2018.06.005. PMID: 30581608; PMCID: PMC6300464.

31. Ravi PR, Aditya N, Patil S, Cherian L. Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv. 2015; 22(7): 903-10. doi: 10.3109/10717544.2013.860501. Epub 2013 Nov 29. PMID: 24286183.

32. Khan S, Patil K, Bobade N, Yeole P, Gaikwad R. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target. 2010 Apr; 18(3):223-34. doi: 10.3109/10611860903386938. PMID: 20030503.

33. I. Somasundaram, S. Sathesh Kumar. Preparation and evaluation of Pramipexole dihydrochloride loaded chitosan nanoparticles for brain-targeting. Research J. Pharm. and Tech. 2017; 10(1): 245-251.

34. Gelperina S, Kostoglou-Athanassiou I. Challenges in nose-to-brain drug delivery systems for neurodegenerative diseases. Journal of Drug Targeting. 2021; 29(5): 567–579.

35. Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; Jun 10; 160(2): 117-34. doi: 10.1016/j.jconrel.2012.03.020. Epub 2012 Mar 29. PMID: 22484195.

36. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6, 286.

37. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013; Jan; 65(1): 36-48. doi: 10.1016/j.addr.2012.09.037. Epub 2012 Oct 1. PMID: 23036225.

38. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics. 2017; Mar 27; 9(2): 12. doi: 10.3390/pharmaceutics9020012. PMID: 28346375; PMCID: PMC5489929.

39. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002; Dec 1; 7(23): 1184-9. doi: 10.1016/s1359-6446(02)02529-1. PMID: 12547019.

40. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013; Jan; 65(1): 36-48. doi: 10.1016/j.addr.2012.09.037. Epub 2012 Oct 1. PMID: 23036225.

41. Wang S, Chen Y, Guo J, Huang Q. Liposomes for Tumor Targeted Therapy: A Review. Int J Mol Sci. 2023; Jan 31; 24(3): 2643. doi: 10.3390/ijms24032643. PMID: 36768966; PMCID: PMC9916501.

42. Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules. 2022; Feb 17; 27(4): 1372. doi: 10.3390/molecules27041372. PMID: 35209162; PMCID: PMC8879473.

43. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011; Mar 18; 63(3): 136-51. doi: 10.1016/j.addr.2010.04.009. Epub 2010 May 2. PMID: 20441782.

44. Illum L. Nasal drug delivery - recent developments and future prospects. J Control Release. 2012; Jul 20; 161(2): 254-63. doi: 10.1016/j.jconrel.2012.01.024. Epub 2012 Jan 24. PMID: 22300620.

45. Kalaiselvi S, Manimaran V, Damodharan N. Nanoparticle as a powerful tool to penetrate the Blood-brain barrier in the treatment of Neurodegenerative disease: Focus on recent advances. Research J. Pharm. and Tech. 2020; 13(5): 2135-2143.

46. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007; Oct; 4(4): 297-305. doi: 10.2174/156720107782151269. PMID: 17979650.

47. Katare DP, Modi S, Chaurasia M. Lipid-based nanocarriers in brain-targeted drug delivery. Journal of Drug Targeting. 2019; 27(5-6): 493–505.

48. Sharma G, Sharma AR, Lee SS, Bhattacharya M, Nam JS, Chakraborty C. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. Int J Pharm. 2019 Mar 25; 559: 360-372. doi: 10.1016/j.ijpharm.2019.01.056. Epub 2019 Feb 2. PMID: 30721725.

49. Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021; May 15; 601: 120571. doi: 10.1016/j.ijpharm.2021.120571. Epub 2021 Apr 2. PMID: 33812967.

50. La-Beck NM, Gabizon AA. Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy. Front Immunol. 2017; Apr 6; 8: 416. doi: 10.3389/fimmu.2017.00416. PMID: 28428790; PMCID: PMC5382151.

51. Javadzadeh Y, Zare K. In situ gel systems for nasal delivery: A review. European Journal of Pharmaceutical Sciences. 2020; 144: 105215.

52. Wang X, Liu G, Ma J, Guo S, Gao L, Jia Y, Li X, Zhang Q. In situ gel-forming system: an attractive alternative for nasal drug delivery. Crit Rev Ther Drug Carrier Syst. 2013;30(5):411-34. doi: 10.1615/critrevtherdrugcarriersyst.2013007362. PMID: 24099327.

53. Oliveira JT, Martins L, Picciochi R, Malafaya PB, Sousa RA, Neves NM, Mano JF, Reis RL. Gellan gum: a new biomaterial for cartilage tissue engineering applications. J Biomed Mater Res A. 2010; Jun 1; 93(3): 852-63. doi: 10.1002/jbm.a.32574. PMID: 19658177.

54. Hiremath SP, Dasankoppa FS, Nadaf A, Jamakandi VG, Mulla JS, Sholapur HN. Formulation and evaluation of a novel in situ gum based ophthalmic drug delivery system of linezolid. Scientia Pharmaceutica. 2008;76(3): 515-532.

55. Laffleur F, Bauer B. Progress in nasal drug delivery systems. Int J Pharm. 2021; Sep 25; 607: 120994. doi: 10.1016/j.ijpharm.2021.120994. Epub 2021 Aug 12. PMID: 34390810.

56. Muhammad U. Ghori, Mohammed H. Mahdi, Alan M. Smith, Barbara R. Conway. Nasal Drug Delivery Systems: An Overview. American Journal of Pharmacological Sciences. Vol. 3, No. 5, 2015, pp 110-119. https://pubs.sciepub.com/ajps/3/5/2

57. Chen Y, Zhang C, Huang Y, Ma Y, Song Q, Chen H, Jiang G, Gao X. Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway. Adv Drug Deliv Rev. 2024; Apr; 207: 115196. doi: 10.1016/j.addr.2024.115196. Epub 2024 Feb 7. PMID: 38336090.

58. Sung YK, Kim SW. Recent advances in polymeric drug delivery systems. Biomater Res. 2020; Jun 6; 24: 12. doi: 10.1186/s40824-020-00190-7. PMID: 32537239; PMCID: PMC7285724.

59. Garg A, Agrawal R, Singh Chauhan C, Deshmukh R. In-situ gel: A smart carrier for drug delivery. Int J Pharm. 2024; Mar 5; 652: 123819. doi: 10.1016/j.ijpharm.2024.123819. Epub 2024 Jan 18. PMID: 38242256.

60. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; Feb; 4(2): 145-60. doi: 10.1038/nrd1632. PMID: 15688077.

61. Fan Y, Marioli M, Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. J Pharm Biomed Anal. 2021; Jan 5; 192: 113642. doi: 10.1016/j.jpba.2020.113642. Epub 2020 Sep 19. PMID: 33011580.

62. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013; Jan; 65(1): 36-48. doi: 10.1016/j.addr.2012.09.037. Epub 2012 Oct 1. PMID: 23036225.

63. Basak SC, Chatterjee A. Advances in in situ gel-forming drug delivery systems for nasal administration: A review. Drug Development and Industrial Pharmacy. 2018; 44(5): 764–772. doi: 10.1080/03639045.2017.1416146

64. Ravi PR, Aditya N, Patil S, Cherian L. Nasal in-situ gels for delivery of rasagiline mesylate: Improvement in bioavailability and brain localization. Drug Delivery. 2017; 22(7): 903–910. doi: 10.3109/10717544.2014.934972

65. aur R, Tiwari S. Formulation and evaluation of in situ gel for intranasal delivery of drugs: A review. Journal of Drug Delivery Science and Technology. 2018; 44: 93–104. doi: 10.1016/j.jddst.2017.10.014

66. Javadzadeh Y, Zare K. In situ gel systems for nasal delivery: A review. European Journal of Pharmaceutical Sciences. 2020; 144: 105215. doi: 10.1016/j.ejps.2019.105215

67. Rao M, Agrawal DK, Shirsath C. Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson’s disease. Drug Development and Industrial Pharmacy. 2017; 43(2): 142–150.

68. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews. 2013; 65(1): 36–48.

69. Allen TM, Cullis PR. Liposomal drug delivery systems: Current applications and future prospects. Nature Reviews Drug Discovery. 2019; 18(1): 25–36.

70. Wu Y, Lim LY. Formulation optimization of novel proniosomes for effective transdermal delivery of piroxicam. International Journal of Pharmaceutics. 2016; 500(1-2): 117–126.

71. Plaza-Oliver M, Santander-Ortega MJ, Lozano MV. Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Deliv Transl Res. 2021; Apr; 11(2): 471-497. doi: 10.1007/s13346-021-00908-7. Epub 2021 Feb 2. PMID: 33528830; PMCID: PMC7852471.

72. Wu H, Zhou Y, Wang Y, Tong L, Wang F, Song S, Xu L, Liu B, Yan H, Sun Z. Current State and Future Directions of Intranasal Delivery Route for Central Nervous System Disorders: A Scientometric and Visualization Analysis. Front Pharmacol. 2021; Jul 12; 12: 717192. doi: 10.3389/fphar.2021.717192. PMID: 34322030; PMCID: PMC8311521.

73. Gayatri D Patil, Aditya R Nikam, Paresh A. Patil, Aakash D. Sonar. Nose to Brain Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(4): 335-0.

74. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013 Feb;3(1):42-62. doi: 10.1007/s13346-012-0108-9. Epub 2012 Oct 18. PMID: 23316447; PMCID: PMC3539067.

75. Manoj K. Baladaniya, Ankit P. Karkar, Nirav V. Patel. Review on Drug Delivery to the Central Nervous System: Novel Approaches. Res. J. Pharm. Dosage Form. and Tech. 2014; 6(4): Oct.- Dec. 253-266.

76. R. Nagaraju, U. Rajeswari, G. Ravi, P. Subhash Chandra Bose, Damineni Saritha. Development and in vitro Characterization of Intranasal Microemulsions of Sumatriptan Succinate for brain Targeting. Research Journal of Pharmacy and Technology. 2021; 14(4): 2062-8.

77. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013; Feb 22; 8(1): 102. doi: 10.1186/1556-276X-8-102. PMID: 23432972; PMCID: PMC3599573.

78. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006; 1(3): 297-315. PMID: 17717971; PMCID: PMC2426795.

79. Anupam Sarma, Malay K. Das, Tapash Chakraborty, Sanjoy Das. Nanostructured lipid carriers (NLCs)-based intranasal Drug Delivery System of Tenofovir disoproxil fumerate (TDF) for brain targeting. Research J. Pharm. and Tech. 2020; 13(11): 5411-5424.

80. Liu Y, Castro Bravo KM, Liu J. Targeted liposomal drug delivery: a nanoscience and biophysical perspective. Nanoscale Horiz. 2021; Feb 1; 6(2): 78-94. doi: 10.1039/d0nh00605j. Epub 2021 Jan 5. PMID: 33400747.

81. Ravi PR, Aditya N, Patil S, Cherian L. Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv. 2015; 22(7): 903-10. doi: 10.3109/10717544.2013.860501. Epub 2013 Nov 29. PMID: 24286183.

82. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol. 2015; Dec 1; 6: 286. doi: 10.3389/fphar.2015.00286. PMID: 26648870; PMCID: PMC4664963.

83. Nagayasu A, Uchiyama K, Kiwada H. The size of liposomes: a factor which affects their targeting efficiency. Advanced Drug Delivery Reviews. 1999; 40(1-2): 75–87.

84. Khan S, et al. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency. Journal of Drug Targeting. 2018; 18(3): 223–234.

85. Lungare S, Bowen J, Badhan R. Development and evaluation of a novel intranasal spray for the delivery of amantadine. Journal of Pharmaceutical Sciences. 2016; 105(5): 1209–1220.

86. Desai D, Rane S. Role of in situ gel systems in nasal drug delivery: A review. Pharmaceutical Research. 2015; 32(1): 1–21.

87. Kaur S, Kaur G. Current trends in nasal drug delivery system. Asian Journal of Pharmaceutical Sciences. 2018; 13(6): 492–508.

88. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013; Feb; 3(1): 42-62. doi: 10.1007/s13346-012-0108-9. Epub 2012 Oct 18. PMID: 23316447; PMCID: PMC3539067.

89. Ravi PR, Aditya N, Patil S, Cherian L. Nasal in-situ gels for delivery of rasagiline mesylate: Improvement in bioavailability and brain localization. Drug Delivery. 2015; 22(7): 903–910.

90. Laffleur F, Bauer B. Progress in nasal drug delivery systems. Int J Pharm. 2021; Sep 25; 607: 120994. doi: 10.1016/j.ijpharm.2021.120994. Epub 2021 Aug 12. PMID: 34390810.

91. Sujit Kumar, I. Somasundaram. Development and Evaluation of Pramipexole Dihydrochloride and Piperine Loaded Chitosan Nanoparticles for Improved Treatment of Parkinson’s Disease. Research J. Pharm. and Tech. 2019; 12(12): 5822-5826

92. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012; May 15; 64(7): 614-28. doi: 10.1016/j.addr.2011.11.002. Epub 2011 Nov 15. PMID: 22119441.

93. Culver HR, Clegg JR, Peppas NA. Analyte-Responsive Hydrogels: Intelligent Materials for Biosensing and Drug Delivery. Acc Chem Res. 2017; Feb 21; 50(2): 170-178. doi: 10.1021/acs.accounts.6b00533. Epub 2017 Feb 7. Erratum in: Acc Chem Res. 2018; Oct 16; 51(10): 2600. doi: 10.1021/acs.accounts.8b00411. PMID: 28170227; PMCID: PMC6130197.

94. Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Int J Pharm. 2019; Jun 30; 565: 258-268. doi: 10.1016/j.ijpharm.2019.05.032. Epub 2019 May 13. PMID: 31095983.

95. Khan S, Patil K, Bobade N, Yeole P, Gaikwad R. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target. 2010; Apr; 18(3): 223-34. doi: 10.3109/10611860903386938. PMID: 20030503.

96. Daneshmandi S, Shamsipur M. Hybrid nanocarriers for drug delivery. Drug Development and Industrial Pharmacy. 2022; 48(3): 465–481.

97. Bijo Mathew, Githa Elizebeth Mathew, Shafeer V.P., Mohammed Musthafa C., Femina P. A Green Route Approach of α, β-Unsaturated Ketone Having a Benzimidazole Tail and Their Virtual Screening on the Molecular Descriptors for Predicting the CNS-Druglikeness. Asian J. Research Chem. 2012; 5(1): January 65-68.

98. Mishima T, Fujioka S, Morishita T, Inoue T, Tsuboi Y. Personalized Medicine in Parkinson's Disease: New Options for Advanced Treatments. J Pers Med. 2021; Jul 10; 11(7): 650. doi: 10.3390/jpm11070650. PMID: 34357117; PMCID: PMC8303729.

99. Bharat Bava, Kruti Sharma, Vikas Yadav. Intranasal Drug Delivery System: A Review. Research Journal of Science and Technology. 2024; 16(1): 51-8.

100. Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi SE, Vader P. Extracellular vesicles as drug delivery systems: Why and how? Adv Drug Deliv Rev. 2020; 159: 332-343. doi: 10.1016/j.addr.2020.04.004. Epub 2020 Apr 16.

101. Sarika S. Lokhande. A Review on Intranasal Drug Delivery System with Recent Advancement. Research J. Topical and Cosmetic Sci. 9(1): Jan.-June 2018 page 12-18.

102. Liu H, Zhang Q, Wang S, Weng W, Jing Y, Su J. Bacterial extracellular vesicles as bioactive nanocarriers for drug delivery: Advances and perspectives. Bioact Mater. 2021; Dec 17; 14: 169-181. doi: 10.1016/j.bioactmat.2021.12.006. PMID: 35310361.

103. Sunena, Sumit Kumar, Sulekha, Deepali Tomar, Dinesh Kumar, Vimal Kishore. Applications of Polymeric Nanoparticle in Nose to Brain Drug Delivery. Research Journal of Pharmacy and Technology. 2023; 16(12): 6087-4.

104. Zhao N, Yang Y, Zhang L, Zhang Q, Balbuena L, Ungvari GS, Zang YF, Xiang YT. Quality of life in Parkinson's disease: A systematic review and meta-analysis of comparative studies. CNS Neurosci Ther. 2021; Mar; 27(3): 270-279. doi: 10.1111/cns.13549. Epub 2020 Dec 28.

105. VP Kahale, PR Upadhay, AJ Mhaiskar, PS Shelat, DR Mundhada. To Access the Efficacy of Rutin on 6-Hydroxydopamine induced Animal Model of Memory Impairment in Parkinson’s Disease. Research J. Pharmacology and Pharmacodynamics.2013; 5(6): 2013; 331-336.

Received on 12.12.2024 Revised on 13.01.2025

Accepted on 06.02.2025 Published on 03.03.2025

Available online from March 10, 2025

Res. J. Pharma. Dosage Forms and Tech.2025; 17(1):53-62.

DOI: 10.52711/0975-4377.2025.00008

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.

Drug Category	Drug Name	Brand Name	Manufacturer	Formulation Type	Route of Administration
Dopamine Precursor	Levodopa/Carbidopa	Sinemet®	Merck Sharp & Dohme	Oral tablet	Oral
Dopamine Agonist	Pramipexole	Mirapex®	Boehringer Ingelheim	Oral tablet, ER tablet	Oral
Dopamine Agonist	Ropinirole	Requip®	GlaxoSmithKline	Oral tablet, ER tablet	Oral
Dopamine Agonist	Apomorphine	Apokyn®	Supernus Pharmaceuticals	Subcutaneous injection	Injection (SC)
MAO-B Inhibitor	Rasagiline	Azilect®	Teva Pharmaceuticals	Oral tablet	Oral
COMT Inhibitor	Entacapone	Comtan®	Novartis	Oral tablet	Oral
NMDA Antagonist	Amantadine	Symmetrel®	Endo Pharmaceuticals	Oral capsule, Syrup	Oral

Drug	Formulation	Brand Name	Indications	Manufacturer	Type of Formulation	Ref
Levodopa	Nasal spray	Inbrija®	Parkinson's disease (off-episodes)	Acorda Therapeutics	Liposomal formulation	26
Apomorphine	Nasal spray	Apokyn®	Parkinson's disease (variations in movement)	Supernus Pharmaceuticals	Microemulsion	27
Selegiline	Nasal gel	Emsam®	Parkinson's illness (Adjunct treatment)	Mylan Pharmaceuticals	Nanoparticles	26,27

Drug/Brand Name	Formulation	Manufacturer	Indication	Clinical Data	Ref
Inbrija® (Levodopa)	Levodopa Inhalation Powder (Nasal Spray)	Acorda Therapeutics	Parkinson's disease, off episodes	Fast motor symptom relief within 10 minutes; significant improvement in UPDRS motor scores; common side effects: cough, respiratory infections.	28
Apokyn® (Apomorphine)	Apomorphine Nasal Spray (Under Development)	Supernus Pharmaceuticals	Parkinson's disease, off episodes	Rapid motor improvement within 5-15 minutes; nausea, yawning, and nasal congestion reported as side effects.	29
Selegiline Nasal Gel	Selegiline Nasal Gel (Under Development)	Mylan Pharmaceuticals	Adjunct therapy for Parkinson’s Disease	Preclinical data show higher bioavailability and faster action; longer-lasting symptom relief with fewer systemic side effects.	30
Rasagiline Mesylate	Nasal Gel (Poloxamer 407, Chitosan)	Research (Not Marketed)	In Parkinson's disease, brain targeting	6-fold increase in brain bioavailability; prolonged symptom relief; some nasal irritation reported.	31
Ropinirole Nasal Gel	Nasal Gel (Pluronic F-127, Hydroxypropyl Methylcellulose)	Research (Not Marketed)	In Parkinson's disease, brain targeting	Five-fold brain uptake increase in preclinical models; sustained release and improved bioavailability; no major adverse effects.	32,33